IS7147A - Kristallaefni, sem innihalda malínsýrusalt N-[2-(díetýlamínó)etýl]-5-[(5-flúóro-2-oxó-3H-indól-3-ýlíðen)metýl]-2,4-dímetýl-1H-pýrról-3-karbóoxamíðs, aðferðir við framleiðslu þess og efnasamsetningar þeirra - Google Patents

Kristallaefni, sem innihalda malínsýrusalt N-[2-(díetýlamínó)etýl]-5-[(5-flúóro-2-oxó-3H-indól-3-ýlíðen)metýl]-2,4-dímetýl-1H-pýrról-3-karbóoxamíðs, aðferðir við framleiðslu þess og efnasamsetningar þeirra

Info

Publication number
IS7147A
IS7147A IS7147A IS7147A IS7147A IS 7147 A IS7147 A IS 7147A IS 7147 A IS7147 A IS 7147A IS 7147 A IS7147 A IS 7147A IS 7147 A IS7147 A IS 7147A
Authority
IS
Iceland
Prior art keywords
ylidene
indol
diethylamino
oxo
fluoro
Prior art date
Application number
IS7147A
Other languages
English (en)
Inventor
Hawley Michael
J. Fleck Thomas
P. Prescott Stephen
T. Maloney Mark
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7147(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Publication of IS7147A publication Critical patent/IS7147A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
IS7147A 2001-08-15 2004-02-10 Kristallaefni, sem innihalda malínsýrusalt N-[2-(díetýlamínó)etýl]-5-[(5-flúóro-2-oxó-3H-indól-3-ýlíðen)metýl]-2,4-dímetýl-1H-pýrról-3-karbóoxamíðs, aðferðir við framleiðslu þess og efnasamsetningar þeirra IS7147A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31235301P 2001-08-15 2001-08-15
PCT/US2002/025649 WO2003016305A1 (en) 2001-08-15 2002-08-13 Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof

Publications (1)

Publication Number Publication Date
IS7147A true IS7147A (is) 2004-02-10

Family

ID=23211067

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7147A IS7147A (is) 2001-08-15 2004-02-10 Kristallaefni, sem innihalda malínsýrusalt N-[2-(díetýlamínó)etýl]-5-[(5-flúóro-2-oxó-3H-indól-3-ýlíðen)metýl]-2,4-dímetýl-1H-pýrról-3-karbóoxamíðs, aðferðir við framleiðslu þess og efnasamsetningar þeirra

Country Status (42)

Country Link
US (2) US20030069298A1 (is)
EP (3) EP3168218B1 (is)
JP (1) JP4159988B2 (is)
KR (1) KR100639281B1 (is)
CN (2) CN100364991C (is)
AP (1) AP1660A (is)
AR (1) AR036261A1 (is)
AU (1) AU2002324684B2 (is)
BG (1) BG108553A (is)
BR (1) BR0211612A (is)
CA (1) CA2455050C (is)
CO (1) CO5550431A2 (is)
CU (1) CU23713B7 (is)
CY (1) CY1121552T1 (is)
CZ (1) CZ2004196A3 (is)
DK (2) DK3168218T3 (is)
EA (1) EA006445B9 (is)
EC (1) ECSP044975A (is)
ES (3) ES2705063T3 (is)
GE (1) GEP20063777B (is)
HR (1) HRP20040112B1 (is)
HU (1) HU229206B1 (is)
IL (1) IL160097A0 (is)
IS (1) IS7147A (is)
MA (1) MA27058A1 (is)
ME (1) ME00414B (is)
MX (1) MXPA04001452A (is)
MY (1) MY139383A (is)
NO (1) NO326508B1 (is)
NZ (1) NZ531232A (is)
OA (1) OA12650A (is)
PL (1) PL216524B1 (is)
PT (2) PT3168218T (is)
RS (1) RS53251B (is)
SI (2) SI3168218T1 (is)
SK (1) SK902004A3 (is)
TN (1) TNSN04028A1 (is)
TR (1) TR201900509T4 (is)
TW (1) TWI269796B (is)
UA (1) UA76483C2 (is)
WO (1) WO2003016305A1 (is)
ZA (1) ZA200400706B (is)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160097A0 (en) 2001-08-15 2004-06-20 Upjohn Co Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole 3-ylidene) methyl]2-(dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
TW200418836A (en) * 2002-09-10 2004-10-01 Pharmacia Italia Spa Formulations comprising an indolinone compound
RU2319702C2 (ru) * 2003-10-02 2008-03-20 Фармация Энд Апджон Компани Ллс Негигроскопическая кристаллическая малеатная соль 5-[(z)-(5-фтор-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-n-[(2s)-2-гидрокси-3-морфолин-4-илпропил]-2,4-диметил-1h-пиррол-3-карбоксамида, фармацевтическая композиция и способ лечения рака
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
AU2005275185B2 (en) * 2004-07-22 2011-06-23 Eli Lilly And Company A crystalline variable hydrate of (S)-6-(4-(2-((3-(9H-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinecarbox amide hemisuccinate salt
EP1885355A1 (en) * 2005-05-12 2008-02-13 Pfizer, Inc. Anticancer combination therapy using sunitinib malate
PL1928858T3 (pl) * 2005-09-19 2009-12-31 Zoetis Services Llc Stałe postacie soli pirolo-podstawionego 2-indolinonu
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
EP2220072A2 (en) * 2007-11-21 2010-08-25 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
CA2709083A1 (en) * 2007-12-12 2009-06-18 Medichem S.A. Polymorphic forms of a 3-pyrrole substituted 2-indolinone
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
US20110112164A1 (en) * 2008-02-21 2011-05-12 Generics (Uk) Limited Novel polymorphs and processes for their preparation
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
US20090247767A1 (en) * 2008-03-31 2009-10-01 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
US8466190B2 (en) 2008-04-16 2013-06-18 Natco Pharma Limited Polymorphic forms of Sunitinib base
US8829039B2 (en) 2008-05-23 2014-09-09 Shanghai Institute Of Pharmaceutical Industry Dihydroindolinone derivatives
AR072117A1 (es) * 2008-06-13 2010-08-04 Medichem Sa Procedimiento para preparar una sal de malato 3-pirrol sustituido 2-indolinona, intermediario de sintesis y una composicion farmaceutica que la comprende.
EP2138167A1 (en) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) * 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
CA2730079A1 (en) * 2008-07-10 2010-01-14 Generics [Uk] Limited Processes for the preparation of crystalline forms of sunitinib malate
EP2373642A2 (en) * 2008-07-24 2011-10-12 Teva Pharmaceutical Industries Ltd Process for the preparation of sunitinib malate via sunitinib acetate and their polymorphs
CN102164913A (zh) * 2008-07-24 2011-08-24 麦迪凯姆股份公司 一种3-吡咯替代的2-吲哚酮苹果酸盐的结晶体形式
US20110263670A1 (en) * 2008-08-25 2011-10-27 Vinayak Gore Novel polymorphs of sunitinib and processes for their preparation
JP2012500837A (ja) * 2008-08-25 2012-01-12 ジェネリクス・（ユーケー）・リミテッド 新規な結晶型およびその調製方法
AR073807A1 (es) * 2008-10-10 2010-12-01 Medichem Sa Proceso para preparar el malato de sunitinib, sal de un acido mas debil que el malato como compuesto intermediario, y proceso para preparar dicha sal intermediaria.
EP2181991A1 (en) * 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2373643A4 (en) * 2009-01-02 2013-08-07 Hetero Research Foundation NEW SUNITINIB MALATE POLYMORPHS
CA2758030C (en) 2009-01-16 2019-01-08 Exelixis, Inc. Malate salt of n-(4-{[6,7-bis(methyloxy)quin0lin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
CA2774634A1 (en) 2009-09-16 2011-03-24 Ranbaxy Laboratories Limited Salts of sunitinib
EP2499133A2 (en) * 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
US8916716B2 (en) 2009-11-19 2014-12-23 Ranbaxy Laboratories Limited Process for the preparation of crystalline form II of L-malic acid salt of sunitinib
CA2788709A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2011104555A2 (en) 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
CA2792039A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
AU2011228765A1 (en) 2010-03-18 2012-10-11 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
WO2011128699A2 (en) 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
WO2012145183A2 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2013140232A1 (en) 2012-03-23 2013-09-26 Laurus Labs Private Limited An improved process for the preparation of sunitinib and its acid addition salts thereof
PL399027A1 (pl) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
NZ701324A (en) 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
CA2838587A1 (en) * 2013-10-18 2015-04-18 Hari Babu Matta Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation
US9278955B2 (en) 2013-10-18 2016-03-08 Sun Pharmaceutical Industries Limited Ascorbic acid salt of sunitinib
MY196581A (en) 2013-11-01 2023-04-19 Pfizer Vectors for Expression of Prostate-Associated Antigens
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN104744442B (zh) * 2013-12-25 2019-05-28 江苏豪森药业集团有限公司 苹果酸舒尼替尼的制备方法
RU2567535C1 (ru) * 2014-10-01 2015-11-10 Олег Ростиславович Михайлов КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105712979A (zh) * 2014-12-05 2016-06-29 广州白云山医药集团股份有限公司白云山制药总厂 一种苹果酸舒尼替尼晶型ⅰ的制备方法
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
WO2020216450A1 (en) 2019-04-25 2020-10-29 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
BR112021020690A2 (pt) * 2019-04-18 2021-12-14 Meter Health Inc Métodos e composições para o tratamento de arritmias respiratórias
JP7633786B2 (ja) * 2020-09-18 2025-02-20 日本化薬株式会社 スニチニブリンゴ酸塩を有効成分とする医薬錠剤
KR20240025990A (ko) 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0179053B1 (ko) 1990-10-15 1999-03-20 알렌 제이.스피겔 인돌 유도체
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
KR100286411B1 (ko) 1992-06-05 2001-04-16 더블유. 지. 콜 치환된 트리아졸의 설페이트 염, 이의 제조방법 및 이를 포함하는 약제학적 조성물
DE69427469T2 (de) 1993-03-12 2001-10-31 Pharmacia & Upjohn Co., Kalamazoo Kristallines ceftiofur (freie säure)
US6288057B1 (en) 1994-08-31 2001-09-11 Eli Lilly And Company Physical form of dihydro-2,3-benzodiazepine derivative
DE19503966C2 (de) 1995-02-07 1998-07-02 Mack Chem Pharm Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung
US5597663A (en) * 1995-05-30 1997-01-28 Motorola, Inc. Low temperature molten lithium salt electrolytes for electrochemical cells
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5673451A (en) * 1995-07-06 1997-10-07 Moore; James R. Instructional toothbrush
US20020038021A1 (en) 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US20020045746A1 (en) 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US6066647A (en) 1996-07-29 2000-05-23 Pfizer Inc. Zwitterionic forms of trovafloxacin
GEP20022636B (en) 1996-08-14 2002-02-25 Searle & Co Us 4-[5-Methyl-3-Phenylisoxazol-4-Yl] Benzenesulfonamide, Its Crystal Structure B, Pharmaceutical Composition Containing The Same, Methods For Treatment Or Prophylaxis Of Disorders Caused By Cyclooxygen-2
US6251355B1 (en) 1996-12-25 2001-06-26 Nippon Kayaku Kabushiki Kaisha Fine cisplatin powder and process for the production thereof
US5777185A (en) * 1997-09-09 1998-07-07 Laroche Industries Inc. Production of organic fluorine compounds
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6012678A (en) * 1998-01-26 2000-01-11 The Boeing Company Galley vacuum waste disposal system
HU230799B1 (hu) 1998-06-19 2018-06-28 Teijin Pharma Limited 2-(3-Ciano-4-izobutiloxifenil)-4-metil-5-tiazolkarbonsav polimorf módosulatai és eljárás ezek előállítására
DK1157019T3 (da) * 1998-12-17 2003-07-14 Hoffmann La Roche 4-alkenyl- (og alkynyl-)oxindoler som inhibitorer af cyklinafhængige kinaser, især CDK2
US6239141B1 (en) * 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
ES2367007T3 (es) * 1999-11-24 2011-10-27 Sugen, Inc. Derivados de indolinona ionizables y su uso como ligandos de ptk.
RS50444B (sr) * 2000-02-15 2010-03-02 Sugen Inc. Inhibitori 2-indolinon protein kinaze supstituisani pirolom
US6316672B1 (en) 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
IL160097A0 (en) 2001-08-15 2004-06-20 Upjohn Co Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole 3-ylidene) methyl]2-(dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
US20110112164A1 (en) 2008-02-21 2011-05-12 Generics (Uk) Limited Novel polymorphs and processes for their preparation
WO2009156837A2 (en) 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt

Also Published As

Publication number Publication date
HU229206B1 (en) 2013-09-30
PT1419151E (pt) 2014-03-27
KR100639281B1 (ko) 2006-10-31
PL216524B1 (pl) 2014-04-30
TWI269796B (en) 2007-01-01
CN100364991C (zh) 2008-01-30
SI3168218T1 (sl) 2019-05-31
MY139383A (en) 2009-09-30
NO326508B1 (no) 2008-12-15
EA006445B1 (ru) 2005-12-29
EP1419151A1 (en) 2004-05-19
PL368317A1 (en) 2005-03-21
DK3168218T3 (en) 2019-01-14
HRP20040112B1 (en) 2012-03-31
AR036261A1 (es) 2004-08-25
HRP20040112A2 (en) 2004-06-30
UA76483C2 (en) 2006-08-15
CO5550431A2 (es) 2005-08-31
CA2455050C (en) 2007-02-20
AP2004002976A0 (en) 2004-03-31
EA006445B9 (ru) 2017-02-28
EP2332934B1 (en) 2017-03-01
CN1543462A (zh) 2004-11-03
GEP20063777B (en) 2006-03-27
EP1419151B1 (en) 2014-02-26
EP3168218A1 (en) 2017-05-17
CN100439360C (zh) 2008-12-03
EP2332934A1 (en) 2011-06-15
ME00414B (me) 2011-10-10
AU2002324684B2 (en) 2006-10-05
TNSN04028A1 (fr) 2006-06-01
EA200400183A1 (ru) 2004-08-26
WO2003016305A1 (en) 2003-02-27
MA27058A1 (fr) 2004-12-20
HK1066542A1 (en) 2005-03-24
SK902004A3 (sk) 2005-03-04
ES2453164T3 (es) 2014-04-04
KR20040030074A (ko) 2004-04-08
NZ531232A (en) 2004-11-26
ECSP044975A (es) 2004-03-23
PT3168218T (pt) 2019-01-11
CA2455050A1 (en) 2003-02-27
BR0211612A (pt) 2004-08-24
HK1088008A1 (zh) 2006-10-27
ES2705063T3 (es) 2019-03-21
EP3168218B1 (en) 2018-11-14
TR201900509T4 (tr) 2019-02-21
CY1121552T1 (el) 2020-05-29
BG108553A (bg) 2005-04-30
CN1789264A (zh) 2006-06-21
SI1419151T1 (sl) 2014-04-30
ES2623094T3 (es) 2017-07-10
AP1660A (en) 2006-09-09
CZ2004196A3 (cs) 2005-01-12
IL160097A0 (en) 2004-06-20
ZA200400706B (en) 2005-05-25
MXPA04001452A (es) 2004-05-20
US20070191458A1 (en) 2007-08-16
RS53251B (sr) 2014-08-29
US20030069298A1 (en) 2003-04-10
HUP0700036A2 (en) 2008-10-28
OA12650A (en) 2006-06-19
JP2005503386A (ja) 2005-02-03
DK1419151T3 (da) 2014-03-31
US7435832B2 (en) 2008-10-14
RS10304A (sr) 2007-02-05
NO20041054L (no) 2004-03-12
CU23713B7 (es) 2011-10-05
CU20040029A7 (es) 2008-03-14
JP4159988B2 (ja) 2008-10-01

Similar Documents

Publication Publication Date Title
IS7147A (is) Kristallaefni, sem innihalda malínsýrusalt N-[2-(díetýlamínó)etýl]-5-[(5-flúóro-2-oxó-3H-indól-3-ýlíðen)metýl]-2,4-dímetýl-1H-pýrról-3-karbóoxamíðs, aðferðir við framleiðslu þess og efnasamsetningar þeirra
DK1353917T3 (da) Ny fremgangsmåde til syntesen af 5-(4-fluorphenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrol-3-carboxylsyre phenylamid
DE60218703D1 (de) (-)-1-(3,4-dichlorphenyl)-3-azabicyclo ä3.1.0ühexan, zusammensetzungen davon und verwendung als dopamin-wiederaufnahme-hemmer
UA93351C2 (uk) Похідні фталазіну як інгібітори parp
EA200602196A1 (ru) Производные пиразола, композиции, содержащие эти соединения, и способы применения
EP1765335A4 (en) PYRAZOLAMIDE DERIVATIVES, COMPOSITIONS AND METHODS OF APPLYING THESE COMPOUNDS
DE60003949D1 (de) 5-aryl-1h-1,2,4 triazolverbindungen als cyclooxygenase -2 inhibitoren und dieseenthaltende pharmazeutische zusammensetzungen
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
ATE486597T1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
NO20063268L (no) Fremgangsmate til fremstilling av 1-(2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-metoksybenzyl)quinuklidin-3-amin
GB0425548D0 (en) Radiolabelled ligands
NO20054071L (no) Polymorfer av pyrrol substituerte 2-indolinon protein kinase inhibitorer.
CY1115143T1 (el) Κρυσταλλοι που περιλαμβανουν μηλικο αλας του ν-[2-(διαιθυλαμινο)αιθυλο]-5-[(5-φθορο-1,2-διϋδρο-2-οξο-3η-ινδολ-3-ιλιδενο)μεθυλο]-2,4-διμεθυλο-1η-πυρρολο-3-καρβοξαμιδιου, διεργασιες παρασκευης αυτων και συνθεσεις αυτων
TH69655A (th) ผลึกซึ่งประกอบด้วยเกลือของกรดมาลิคของ 3-ไพร์รอล ซับสทิทิวเทด 2-อินโดลิโนน และสารผสมของสารเหล่านี้
SG145572A1 (en) Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same
RU2002120607A (ru) Замещенные 3-метил-4,5-дигидро-1,2-бензизоксазолы, проявляющие свойства активаторов прорастания семян пшеницы
EP1724256A3 (en) Novel process for the synthesis of 5-(4-fluorphenyl)-1-2(2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl)-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide